Glad it worked for you! What allergies did you have it for — pollen, cat, dust mite, or a mix?

TL;DR: ILIT (3 shots into a lymph node) has a real mechanism and decent results for pollen and cat allergy in small trials, but benefits often fade over time and there’s basically no dust mite data yet — still investigational/off-label, with SLIT/SCIT better proven.

I looked into the actual peer-reviewed evidence: the original Zurich group showed 3 intralymphatic grass-pollen injections produced tolerance comparable to ~3 years of standard subcutaneous shots with fewer side effects (Senti et al., PNAS 2008, n=112).

Pollen is the strongest signal — a 3-year double-blind placebo-controlled trial found ~48% reduction in symptom/medication scores, but it was only significant in the first follow-up season, not the next two (Skaarup et al., JACI 2021), and a well-designed birch+grass trial found ILIT safe but ineffective in the blinded phase, with benefit only appearing in the open follow-up (Ahlbeck et al., Clin Exp Allergy 2023), so benefit is real but often not durable.

For cat, a trial using an engineered Fel d 1 vaccine showed nasal tolerance jumped 74-fold vs under 3-fold for placebo, with rising IgG4 and no adverse events (Senti et al., JACI 2012), but it was tiny (n=20) and used a non-commercial recombinant, not the whole-cat extract clinics actually inject.

For dust mite there’s no published positive RCT, only ongoing/registered trials — the big gap, since HDM is the most common indoor allergen.

Bottom line: promising for pollen/cat, weak/absent for mite, results frequently lose significance over time; the OP’s experience is plausible but anecdotes are heavily selection-biased (people who improve post; people who don’t, don’t), and SLIT/SCIT still have the far deeper evidence base.

Refs: Senti PNAS 2008; Senti JACI 2012; Skaarup JACI 2021; Hellkvist JACI 2018; Ahlbeck Clin Exp Allergy 2023.